877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
New Search

C10H11NO2

Categories

Cyclic compounds (1)
Designer drugs (1)
Drugs acting on the nervous system (1)
Entactogens and empathogens (1)
Food Additives (1)
Heterocyclic compounds (1)
Heterocyclic compounds (3 rings) (1)
Monoamine releasing agents (1)
Psychoactive drugs (1)
Serotonin releasing agents (1)

Suppliers

Sigma Aldrich (32)
Matrix Scientific (25)
Oakwood Chemical (11)
ChemBridge (10)
SynQuest Laboratories (10)
Apollo Scientific (8)
Accela (6)
AK Scientific (6)
Frontier Scientific (5)
TCI Chemicals (5)
Toronto Research Chemicals (1)

ACETOACETANILIDE (102-01-2, 86349-51-1)  
Acetoacetanilide is an organic compound with the formula CH3C(O)CH2C(O)NHC6H5. It is the acetoacetamide derivative of aniline. It is a white solid that is poorly soluble in water.
5-Hydroxytryptophol (154-02-9)  
Hydroxytryptophol
93-17-4 (93-17-4)  
3,4-dimethoxyphenylacetonitrile
132741-81-2 (132741-81-2)  
MDAI (5,6-methylenedioxy-2-aminoindane) is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic and highly selective serotonin releasing agent (SSRA) in vitro and produces entactogen effects in humans.
1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid (35186-99-3, 67123-97-1)  
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, (S)-isomer  ·  1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, hydrochloride, (S)-isomer  ·  1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, (+-)-isomer
5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline (15052-05-8)  
TDIQ (also known as 6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline or MDTHIQ) is a drug used in scientific research, which has anxiolytic and anorectic effects in animals. It has an unusual effects profile in animals, with the effects generalising to cocaine and partially to MDMA and ephedrine, but the effects did not generalise to amphetamine and TDIQ does not have any stimulant effects. It is thought these effects are mediated via a partial agonist action at Alpha-2 adrenergic receptors, and TDIQ has been suggested as a possible drug for the treatment of cocaine dependence.
Next Page >